Digital care firm Teladoc Well being introduced final week it is increasing its major care program, Primary360, with same-day medicine supply and at-home lab assortment.
The brand new providers come by way of partnerships with digital pharmacy Capsule and Scarlet Well being, a division of BioReference Laboratories that gives specimen assortment and supply. It is going to additionally add in-network referrals to its major care instruments.
Teladoc stated the added capabilities will enhance care coordination, making it simpler for sufferers to obtain their prescriptions and full lab checks.
“We’re seeing thrilling momentum with Primary360,” Kelly Bliss, president of U.S. group well being at Teladoc Well being, stated in an announcement. “We additionally know that digital care is a driver in lowering obstacles to healthcare entry, and we embrace the chance and the accountability to additional advance well being fairness with Primary360.”
THE LARGER TREND
Teladoc launched the first care providing to well being plans, employers and different payers within the U.S. in October final yr. Shortly afterward, it introduced a partnership with Trustmark Well being Advantages to provide a virtual-first insurance coverage plan constructed round Primary360.
In February, Teladoc launched a continual care administration program referred to as Persistent Care Full. The virtual-care large stated the brand new program and its psychological well being choices myStrength Full and Primary360, have been accelerated by the corporate’s 2020 merger with continual care administration firm Livongo.
Nonetheless, Teladoc has struggled financially thus far this yr. It reported a $6.7 billion web loss within the first quarter, a big soar from an roughly $200 million loss in Q1 2021. It stated the Q1 loss was pushed primarily by a $6.6 billion noncash goodwill-impairment cost associated to the Livongo acquisition.
In early June, a class motion lawsuit was filed towards Teladoc, CEO Jason Gorevic and CFO Mala Murthy alleging that they had misled buyers about its monetary prospects. In an announcement, Teladoc stated there was “no factual foundation to the swimsuit in any respect.”